273 related articles for article (PubMed ID: 34704415)
1. Research progress on neonatal Fc receptor and its application.
Hu M; Wei S; Zhou W; Wang P
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 50(4):537-544. PubMed ID: 34704415
[TBL] [Abstract][Full Text] [Related]
2. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.
Sockolosky JT; Szoka FC
Adv Drug Deliv Rev; 2015 Aug; 91():109-24. PubMed ID: 25703189
[TBL] [Abstract][Full Text] [Related]
3. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
4. Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention.
Patel DD; Bussel JB
J Allergy Clin Immunol; 2020 Sep; 146(3):467-478. PubMed ID: 32896307
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for pH-insensitive inhibition of immunoglobulin G recycling by an anti-neonatal Fc receptor antibody.
Kenniston JA; Taylor BM; Conley GP; Cosic J; Kopacz KJ; Lindberg AP; Comeau SR; Atkins K; Bullen J; TenHoor C; Adelman BA; Sexton DJ; Edwards TE; Nixon AE
J Biol Chem; 2017 Oct; 292(42):17449-17460. PubMed ID: 28878017
[TBL] [Abstract][Full Text] [Related]
6. Antigen physiochemical properties allosterically effect the IgG Fc-region and Fc neonatal receptor affinity.
Sun Y; Estevez A; Schlothauer T; Wecksler AT
MAbs; 2020; 12(1):1802135. PubMed ID: 32795110
[TBL] [Abstract][Full Text] [Related]
7. FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions.
Challa DK; Velmurugan R; Ober RJ; Sally Ward E
Curr Top Microbiol Immunol; 2014; 382():249-72. PubMed ID: 25116104
[TBL] [Abstract][Full Text] [Related]
8. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn
Mester S; Evers M; Meyer S; Nilsen J; Greiff V; Sandlie I; Leusen J; Andersen JT
MAbs; 2021; 13(1):1893888. PubMed ID: 33691596
[TBL] [Abstract][Full Text] [Related]
9. Implications of Fc Neonatal Receptor (FcRn) Manipulations for Transplant Immunotherapeutics.
Jordan SC; Ammerman N; Vo A
Transplantation; 2020 Jan; 104(1):17-23. PubMed ID: 31397806
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic age of the neonatal Fc receptor.
Pyzik M; Kozicky LK; Gandhi AK; Blumberg RS
Nat Rev Immunol; 2023 Jul; 23(7):415-432. PubMed ID: 36726033
[TBL] [Abstract][Full Text] [Related]
11. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
12. Targeting the neonatal Fc receptor (FcRn) to treat autoimmune diseases and maternal-fetal immune cytopenias.
Wyckoff SL; Hudson KE
Transfusion; 2021 May; 61(5):1350-1354. PubMed ID: 33650699
[TBL] [Abstract][Full Text] [Related]
13. Neonatal Fc receptor and IgG-based therapeutics.
Kuo TT; Aveson VG
MAbs; 2011; 3(5):422-30. PubMed ID: 22048693
[TBL] [Abstract][Full Text] [Related]
14. In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor.
Seijsing J; Yu S; Frejd FY; Höiden-Guthenberg I; Gräslund T
Sci Rep; 2018 Mar; 8(1):5141. PubMed ID: 29572538
[TBL] [Abstract][Full Text] [Related]
15. Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization.
Foss S; Grevys A; Sand KMK; Bern M; Blundell P; Michaelsen TE; Pleass RJ; Sandlie I; Andersen JT
J Control Release; 2016 Feb; 223():42-52. PubMed ID: 26718855
[TBL] [Abstract][Full Text] [Related]
16. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
Gurbaxani B; Dostalek M; Gardner I
Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
[TBL] [Abstract][Full Text] [Related]
17. Characterization and screening of IgG binding to the neonatal Fc receptor.
Neuber T; Frese K; Jaehrling J; Jäger S; Daubert D; Felderer K; Linnemann M; Höhne A; Kaden S; Kölln J; Tiller T; Brocks B; Ostendorp R; Pabst S
MAbs; 2014; 6(4):928-42. PubMed ID: 24802048
[TBL] [Abstract][Full Text] [Related]
18. [Neonatal Fc receptor (FcRn)-A Novel Therapeutic Approach for Autoimmune Disease].
Murai H; Harada D
Brain Nerve; 2024 Feb; 76(2):183-191. PubMed ID: 38351566
[TBL] [Abstract][Full Text] [Related]
19. Exploiting the neonatal crystallizable fragment receptor to treat kidney disease.
Dylewski JF; Haddad G; Blaine J
Kidney Int; 2024 Jan; 105(1):54-64. PubMed ID: 38707675
[TBL] [Abstract][Full Text] [Related]
20. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
